Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Income towards Parent Company (2021 - 2026)

Zentalis Pharmaceuticals has reported Income towards Parent Company over the past 6 years, most recently at -$35.4 million for Q1 2026.

  • For Q1 2026, Income towards Parent Company rose 26.78% year-over-year to -$35.4 million; the TTM value through Mar 2026 reached -$124.1 million, up 43.82%, while the annual FY2025 figure was -$137.1 million, 17.37% up from the prior year.
  • Income towards Parent Company for Q1 2026 was -$35.4 million at Zentalis Pharmaceuticals, roughly flat from -$35.2 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $10.0 million in Q1 2024 and troughed at -$99.0 million in Q2 2023.
  • A 5-year average of -$49.2 million and a median of -$48.4 million in 2022 define the central range for Income towards Parent Company.
  • Biggest five-year swings in Income towards Parent Company: crashed 9063.45% in 2022 and later soared 116.42% in 2024.
  • Year by year, Income towards Parent Company stood at -$48.4 million in 2022, then decreased by 26.17% to -$61.0 million in 2023, then rose by 22.24% to -$47.5 million in 2024, then increased by 25.82% to -$35.2 million in 2025, then dropped by 0.39% to -$35.4 million in 2026.
  • Business Quant data shows Income towards Parent Company for ZNTL at -$35.4 million in Q1 2026, -$35.2 million in Q4 2025, and -$26.7 million in Q3 2025.